| Dr Ramon A Batson, MD | |
|
33 Hospital Ave., Danbury, CT 06810 | |
| (203) 792-2003 | |
| (203) 739-8926 |
| Full Name | Dr Ramon A Batson |
|---|---|
| Gender | Male |
| Speciality | Neurosurgery |
| Experience | 44 Years |
| Location | 33 Hospital Ave., Danbury, Connecticut |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1275574238 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207T00000X | Neurological Surgery | 27233 (Connecticut) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Danbury Hospital | Danbury, CT | Hospital |
| Norwalk Hospital | Norwalk, CT | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Nuvance Health Medical Practice Ct Inc | 4789597691 | 648 |
News Archive
Curie-Cancer, the body which leads the Institut Curie's industry partner research activity, and Servier, today announce that they have renewed their partnership with the aim of identifying therapeutic targets for treating ‘triple negative' breast cancers. The partnership will continue for a further three years.
Astellas Pharma US, Inc. and Medivation, Inc. today announced results of a national survey of men with advanced prostate cancer and caregivers of men with advanced prostate cancer.
Cyclacel Pharmaceuticals, Inc. announced today interim response data from a Phase 2 randomized trial of oral sapacitabine capsules, a novel nucleoside analogue, in older patients with myelodysplastic syndromes (MDS) that have failed hypomethylating agents. The data were presented at an oral poster discussion session at the 2010 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois.
The COVID-19 pandemic has highlighted the need for rapid and accurate nucleic acid detection at the point of care. To meet this need, scientists from the Suzhou Institute of Biomedical Engineering and Technology have developed a novel amplification-free rapid SARS-CoV-2 nucleic acid detection platform based on hybrid capture fluorescence immunoassay (HC-FIA).
› Verified 1 days ago
| Entity Name | Danbury Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1548293343 PECOS PAC ID: 1557273935 Enrollment ID: O20031104000476 |
News Archive
Curie-Cancer, the body which leads the Institut Curie's industry partner research activity, and Servier, today announce that they have renewed their partnership with the aim of identifying therapeutic targets for treating ‘triple negative' breast cancers. The partnership will continue for a further three years.
Astellas Pharma US, Inc. and Medivation, Inc. today announced results of a national survey of men with advanced prostate cancer and caregivers of men with advanced prostate cancer.
Cyclacel Pharmaceuticals, Inc. announced today interim response data from a Phase 2 randomized trial of oral sapacitabine capsules, a novel nucleoside analogue, in older patients with myelodysplastic syndromes (MDS) that have failed hypomethylating agents. The data were presented at an oral poster discussion session at the 2010 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois.
The COVID-19 pandemic has highlighted the need for rapid and accurate nucleic acid detection at the point of care. To meet this need, scientists from the Suzhou Institute of Biomedical Engineering and Technology have developed a novel amplification-free rapid SARS-CoV-2 nucleic acid detection platform based on hybrid capture fluorescence immunoassay (HC-FIA).
› Verified 1 days ago
| Entity Name | Nuvance Health Medical Practice Ct Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1407898117 PECOS PAC ID: 4789597691 Enrollment ID: O20031205000130 |
News Archive
Curie-Cancer, the body which leads the Institut Curie's industry partner research activity, and Servier, today announce that they have renewed their partnership with the aim of identifying therapeutic targets for treating ‘triple negative' breast cancers. The partnership will continue for a further three years.
Astellas Pharma US, Inc. and Medivation, Inc. today announced results of a national survey of men with advanced prostate cancer and caregivers of men with advanced prostate cancer.
Cyclacel Pharmaceuticals, Inc. announced today interim response data from a Phase 2 randomized trial of oral sapacitabine capsules, a novel nucleoside analogue, in older patients with myelodysplastic syndromes (MDS) that have failed hypomethylating agents. The data were presented at an oral poster discussion session at the 2010 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois.
The COVID-19 pandemic has highlighted the need for rapid and accurate nucleic acid detection at the point of care. To meet this need, scientists from the Suzhou Institute of Biomedical Engineering and Technology have developed a novel amplification-free rapid SARS-CoV-2 nucleic acid detection platform based on hybrid capture fluorescence immunoassay (HC-FIA).
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Ramon A Batson, MD 33 Hospital Ave., Danbury, CT 06810 Ph: (203) 792-2003 | Dr Ramon A Batson, MD 33 Hospital Ave., Danbury, CT 06810 Ph: (203) 792-2003 |
News Archive
Curie-Cancer, the body which leads the Institut Curie's industry partner research activity, and Servier, today announce that they have renewed their partnership with the aim of identifying therapeutic targets for treating ‘triple negative' breast cancers. The partnership will continue for a further three years.
Astellas Pharma US, Inc. and Medivation, Inc. today announced results of a national survey of men with advanced prostate cancer and caregivers of men with advanced prostate cancer.
Cyclacel Pharmaceuticals, Inc. announced today interim response data from a Phase 2 randomized trial of oral sapacitabine capsules, a novel nucleoside analogue, in older patients with myelodysplastic syndromes (MDS) that have failed hypomethylating agents. The data were presented at an oral poster discussion session at the 2010 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois.
The COVID-19 pandemic has highlighted the need for rapid and accurate nucleic acid detection at the point of care. To meet this need, scientists from the Suzhou Institute of Biomedical Engineering and Technology have developed a novel amplification-free rapid SARS-CoV-2 nucleic acid detection platform based on hybrid capture fluorescence immunoassay (HC-FIA).
› Verified 1 days ago
Jeffrey Gilligan, M.D. Neurological Surgery Medicare: Medicare Enrolled Practice Location: 33 Hospital Ave., Danbury, CT 06810 Phone: 203-792-2003 Fax: 203-739-8926 | |
Dr. Joshua D Marcus, M.D. Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 33 Hospital Ave., Danbury, CT 06810 Phone: 203-792-2003 Fax: 203-739-8926 | |
Scott P Sanderson, M.D. Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 33 Hospital Ave., Danbury, CT 06810 Phone: 203-792-2003 Fax: 203-739-8926 |